呼吸道合胞病毒相关住院后心肺事件风险
该自我对照病例系列研究纳入2017年1月1日至2024年3月31日期间11 887例有RSV相关住院且至少发生一次心肺事件(心梗、卒中、慢阻肺急性加重、充血性心衰加重、心律失常)的成人(平均年龄69.4岁,女性61.4%)。采用条件泊松回归比较RSV住院索引日期后180天内(风险期)与索引日期前21天以上或后180天以上(对照期)的心肺事件发生率。结果显示住院后前14天各心肺事件风险均升高,前7天IRR最高:心梗8.7(95%CI 6.7-11.2)、卒中7.4(95%CI 5.5-10.1)、心衰加重12.5(95%CI 10.5-14.8)、慢阻肺加重23.1(95%CI 20.2-26.5)、心律失常16.5(95%CI 14.5-18.7),部分事件风险显著升高持续至180天。作者认为研究结果强化了增加成人RSV免疫接种的必要性。
要点
- RSV住院后第1-7天心梗IRR 8.7(95%CI 6.7-11.2),第8-14天降至5.2(95%CI 3.7-7.2),第15-21天2.6(95%CI 1.6-4.3)。
- RSV住院后第1-7天卒中IRR 7.4(95%CI 5.5-10.1),第8-14天5.9(95%CI 4.2-8.3),第15-21天3.7(95%CI 2.3-5.9)。
- RSV住院后第1-7天充血性心衰加重IRR 12.5(95%CI 10.5-14.8),第8-14天4.1(95%CI 3.1-5.5),第15-21天2.4(95%CI 1.6-3.6)。
- RSV住院后第1-7天慢阻肺急性加重IRR 23.1(95%CI 20.2-26.5),第15-21天降至1.3(95%CI 0.8-2.4),未达统计学显著。
- RSV住院后第1-7天心律失常IRR 16.5(95%CI 14.5-18.7),第15-21天降至1.6(95%CI 1.1-2.5)。
适用人群与场景
- 年龄≥18岁、有1次或以上RSV相关住院且至少发生1次心肺事件(心梗、卒中、慢阻肺急性加重、充血性心衰加重、心律失常)的成人。
- 数据来源于去标识化的Optum Market Clarity数据集,观察期为2017年1月1日至2024年3月31日。
诊断标准与关键阈值
- RSV相关住院及结局基于诊断代码识别。
- 风险期为RSV相关住院索引日期后≤180天;对照期为索引日期前>21天或后>180天。
研究设计与关键结果
- 研究类型为自我对照病例系列研究,纳入11 887例患者(平均年龄69.4岁,SD 15.5;女性7303例,61.4%)。
- 心梗IRR:第1-7天8.7(95%CI 6.7-11.2),第8-14天5.2(95%CI 3.7-7.2),第15-21天2.6(95%CI 1.6-4.3)。
- 卒中IRR:第1-7天7.4(95%CI 5.5-10.1),第8-14天5.9(95%CI 4.2-8.3),第15-21天3.7(95%CI 2.3-5.9)。
- 充血性心衰加重IRR:第1-7天12.5(95%CI 10.5-14.8),第8-14天4.1(95%CI 3.1-5.5),第15-21天2.4(95%CI 1.6-3.6)。
- 慢阻肺急性加重IRR:第1-7天23.1(95%CI 20.2-26.5),第15-21天1.3(95%CI 0.8-2.4)。
- 心律失常IRR:第1-7天16.5(95%CI 14.5-18.7),第15-21天1.6(95%CI 1.1-2.5)。
- 部分心肺事件风险显著升高持续至住院后180天。
证据类型、等级与局限
- 证据类型:自我对照病例系列研究。
- 作者结论:RSV与流感及SARS-CoV-2类似,与RSV相关住院后2周内心肺事件风险升高相关,部分疾病风险显著升高持续至入院后180天。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果强化了增加成人RSV免疫接种的必要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Respiratory syncytial virus (RSV) may trigger cardiorespiratory events in adults.
OBJECTIVE: To assess the risk of cardiorespiratory events in the 180 days following RSV-related hospitalization compared with a control period in adults.
DESIGN, SETTING, AND PARTICIPANTS: This self-controlled case series study had an observation period from January 1, 2017, through March 31, 2024. Data were obtained from the deidentified Optum Market Clarity Dataset, including RSV-related hospitalization and associated outcomes, which were identified based on diagnosis codes. Adults with 1 or more RSV-related hospitalizations and 1 or more cardiorespiratory events (myocardial infarction [MI], stroke, chronic obstructive pulmonary disease [COPD] exacerbation, congestive heart failure [CHF] exacerbation, and arrhythmia) were included.
EXPOSURE: RSV-related hospitalization.
MAIN OUTCOMES AND MEASURES: A conditional Poisson regression model was fitted to compare the incidence of cardiorespiratory events during the risk period (ie, ≤180 days after RSV-related hospital index date) and control periods (ie, >21 days before or >180 days after the index date). Incidence rate ratios (IRRs) and 95% CIs were estimated and adjusted for time-varying covariates.
RESULTS: A total of 11 887 patients (mean [SD] age, 69.4 [15.5] years; 7303 females [61.4%]) with RSV-related hospitalization were included. An increased risk was associated with each cardiorespiratory event during the first 14 days following RSV-related hospitalization, with the highest IRR estimates observed in the initial 7 days. For MI, the IRRs were 8.7 (95% CI, 6.7-11.2) during days 1 to 7, decreasing to 5.2 (95% CI, 3.7-7.2) during days 8 to 14 and 2.6 (95% CI, 1.6-4.3) during days 15 to 21. For stroke, the IRRs were 7.4 (95% CI, 5.5-10.1), 5.9 (95% CI, 4.2-8.3), and 3.7 (95% CI, 2.3-5.9) during the first 3 weeks with a similar pattern for CHF exacerbation (12.5 [95% CI, 10.5-14.8], 4.1 [95% CI, 3.1-5.5], and 2.4 [95% CI, 1.6-3.6], respectively). For COPD exacerbation and arrhythmia, the IRRs decreased during the first 3 weeks from 23.1 (95% CI, 20.2-26.5) through day 7 to 1.3 (95% CI, 0.8-2.4) during days 15 to 21 and from 16.5 (95% CI, 14.5-18.7) to 1.6 (95% CI, 1.1-2.5), respectively.
CONCLUSIONS AND RELEVANCE: This study demonstrated that RSV, similar to influenza and SARS-CoV-2, was associated with an increased risk of cardiorespiratory events 2 weeks following RSV-related hospitalization, and some conditions had significant risk elevations up to 180 days after admission. The findings reinforce the need to increase RSV immunization in adults.
参考来源
- Liang C, Judy J, Aliabadi N, et al. Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus-Related Hospitalization. JAMA Netw Open. 2026. PMID: 41632477. doi:10.1001/jamanetworkopen.2025.56767
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。